Cognitive assessment software provider, Cambridge Cognition (COG) , revealed on Friday part of a regulatory development progress with developed drug, aducanumab, to address Alzheimer's disease.
Following a recent consultation with the U.S. Food and Drug Administration, Biotechnology firm, Biogen, alongside Japanese pharmaceutical company, Eisai, announced plans to pursue approval for aducanumab, an antibody studied for the treatment of Alzheimer's disease.
"We were delighted to hear the news of Biogen's re-invigorated Alzheimer's programme, as it holds promise for the millions of people worldwide who are affected by the disease,” said Chief Executive, Matthew Stork.
Despite initial concerns about efficacy, renewed analysis of aducanumab recently revealed positive results at higher doses of the drug and Biogen have now indicated that they’ll file for approval in the U.S. early 2020.
This development would mark a “major therapeutic breakthrough”, the company explained, with no new treatments approved since 2003 -- if approved, this new treatment would be the first of its king to slow the progression of Alzheimer's disease.
Cambridge Cognition’s CANTAB assessment solutions are specifically sensitive to the early cognitive decline during Alzheimer's disease therefore making this pursuit a promising opportunity for the group.
Mr Stork says the medical device can help clinicians in “identifying the right patients” for these potential new treatments -- the FDA-cleared CANTAB MobileTM delivers assessments in order to distinguish older patients who have concerns about their memory from those at increased risk of dementia.
“We are therefore preparing for the approval of disease modifying treatments so that patients and families can benefit from new therapies as soon as possible,'' Mr Stork added.
Follow News & Updates from Cambridge Cognition here: